CTN Dissemination Library

  • Browse & Search
    • Search the CTN Library
    • In press articles
    • Search the site/blog
  • Nodes
  • Protocols
  • Training
    • CTN & Other Training
    • Upcoming Events
  • Resources
    • What’s New Blog
    • NIDA CTN Site
    • CTN Bulletin
    • CTN Common Data Elements (CDE)
    • CTN Directory (2025)
    • PATHS Toolkit
    • Implementation
    • General Resources
  • About Us
  • Browse & Search
    • Search the CTN Library
    • In press articles
    • Search the site/blog
  • Nodes
  • Protocols
  • Training
    • CTN & Other Training
    • Upcoming Events
  • Resources
    • What’s New Blog
    • NIDA CTN Site
    • CTN Bulletin
    • CTN Common Data Elements (CDE)
    • CTN Directory (2025)
    • PATHS Toolkit
    • Implementation
    • General Resources
  • About Us
  • Sex differences in comorbid mental and substance use disorders among primary care patients with opioid use disorder.

    Braciszewski JM, et al. Sex differences in comorbid mental and substance use disorders among primary care patients with opioid use disorder. Psychiatric Services 2022;73(12):1330-1337.

    Read More
  • The association between buprenorphine treatment duration and mortality: A multi-site cohort study of people who discontinued treatment.

    Glanz JM, et al. The association between buprenorphine treatment duration and mortality: A multi-site cohort study of people who discontinued treatment. Addiction 2022;118(1):97-107.

    Read More
  • Time-lagged association between counseling and/or 12-step attendance with subsequent opioid use in a secondary analysis from a randomized, clinical trial of medications for opioid use disorder.

    Hefner K, Choo T, Shmueli-Blumberg D, Pavlicova M, King J, Fishman M, Shulman M, Campbell ANC, Greiner M, Scodes J, Meyers-Ohki S, Novo P, Nunes EV, Rotrosen J. Time-lagged association between counseling and/or 12-step attendance with subsequent opioid use in a secondary analysis from a randomized, clinical trial of medications for opioid use disorder. Drug and Alcohol Dependence Reports 2022;5:100100.

    Read More
  • Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder.

    Rudolph KE, Williams NT, Goodwin ATS, Shulman M, Fishman M, Diaz I, Luo S, Rotrosen J, Nunes EV. Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder. Drug and Alcohol Dependence 2022;239:109609.

    Read More
  • Five-year incidence of substance use and mental health diagnoses following exposure to opioids or opioids with benzodiazepines during an emergency department encounter for traumatic injury.

    Sprunger JG, Johnson K, Lewis DF, Kaelber DC, Winhusen TJ. Five-year incidence of substance use and mental health diagnoses following exposure to opioids or opioids with benzodiazepines during an emergency department encounter for traumatic injury. Drug and Alcohol Dependence 2022;238:109584.

    Read More
  • Relative effectiveness of social media, dating apps, and information search sites in promoting HIV self-testing: Observational cohort study.

    Stafylis C, Vavala G, Wang Q, McLeman B, Lemley SM, Young SD, Xie H, Matthews AG, Oden N, Revoredo L, Shmueli-Blumberg D, Hichborn EG, McKelle E, Moran LM, Jacobs P, Marsch LA, Klausner JD. Relative effectiveness of social media, dating apps, and information search sites in promoting HIV self-testing: Observational cohort study. JMIR Formative Research 2022;6(9):e35648.

    Read More
  • Emergency department utilization for substance use disorders and mental health conditions during COVID-19.

    Venkatesh AK, Janke AT, Kinsman J, Rothenberg C, Goyal P, Malicki C, D'Onofrio G, Taylor A, Hawk K. Emergency department utilization for substance use disorders and mental health conditions during COVID-19. PLoS One 2022;17(1):e262136.

    Read More
  • Under-representation of key demographic groups in opioid use disorder trials.

    Rudolph KE, Russell M, Luo SX, Rotrosen J, Nunes EV. Under-representation of key demographic groups in opioid use disorder trials. Drug and Alcohol Dependence Reports 2022;4:100084.

    Read More
  • Patient characteristics associated with opioid abstinence after participation in a trial of buprenorphine versus injectable naltrexone.

    Greiner MG, Shulman M, Scodes J, Choo T, Pavlicova M, Opara O, Campbell ANC, Novo P, Fishman MJ, Lee JD, Rotrosen J, Nunes EV. Patient characteristics associated with opioid abstinence after participation in a trial of buprenorphine versus injectable naltrexone. Substance Use & Misuse 2022;57(11): 1732-1742.

    Read More
  • Association between treatment setting and outcomes among Oregon Medicaid patients with opioid use disorder: A retrospective cohort study.

    Hartung DM, Markwardt S, Johnston K, Geddes J, Baker R, Leichtling G, Hildebran C, Chan B, Cook RR, McCarty D, Ghitza U, Korthuis PT. Association between treatment setting and outcomes among Oregon Medicaid patients with opioid use disorder: A retrospective cohort study. Addiction Science & Clinical Practice 2022;14:45.

    Read More
1920212223

Recent Posts

  • Now in the CTN Library: NIDA CTN Common Data Elements
  • New in the Library (March – April 2026)
  • CTN Primary Care SIG Webinar: Conducting Substance Use Research in Prison (March 23, 2026, 12pm ET)
  • New in the Library (February – March 2026)
  • News from the Appalachian Node: Brief Report for CTN-0135 Published

Recent Comments

No comments to show.

Archives

  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • September 2022

Categories

  • DSC News
  • Events
  • Funding
  • Jobs
  • New in the Library
  • Node News
  • Other
  • Protocol News
  • SIG Updates
  • Uncategorized
Supported by a grant from the National Institute on Drug Abuse to the University of Washington Department of Psychiatry & Behavioral Science's Addictions, Drug & Alcohol Institute (ADAI). The materials on this site have neither been created nor reviewed by NIDA.